Loading clinical trials...

The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab

Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity

NCT07052877•Royal North Shore Hospital

View on ClinicalTrials.gov

Summary

This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\> 18 year of age
•ECOG 0-2
•Able to provide informed consent for the study
•Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
•Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
•For bevacizumab treatment as per treating physician
•Able to comply with trial requirements

Exclusion Criteria

•No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
•Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
•Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
•Does not fulfill PBS requirements for bevacizumab
•Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study

Locations (1)

Royal North Shore Hospital

Saint Leonards, New South Wales, Australia

Key Dates

Start Date

July 1, 2025

Primary Completion Date

July 1, 2027

Completion Date

July 1, 2027

Last Updated

July 11, 2025

Enrollment

ESTIMATED participants

Conditions

GlioblastomaGlioblastoma Multiforme (GBM)

Interventions

PSMA PET/CT scan

DIAGNOSTIC_TEST

Contacts

Alexander Yuile

CONTACT

+61 2 94631171 Alexander.Yuile@health.nsw.gov.au

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant+5 more

View study

RECRUITING

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

High Grade GliomaDiffuse Intrinsic Pontine Glioma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 11, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Targeted Pediatric High-Grade Glioma Therapy

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma